We are live on ! Find out more
VRNA

Verona Pharma
VRNA

Delisted

VRNA was delisted on the 6th of October, 2025.

Back to rankings

14 hedge funds and large institutions have $132M invested in Verona Pharma in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

66% more capital invested

Capital invested by funds: $79.3M → $132M (+$52.3M)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

17% more funds holding

Funds holding: 12 → 14 (+2)

0.09% less ownership

Funds ownership: 6.36% → 6.27% (-0.09%)

Holders
14
Holders Change
+2
Holders Change %
+16.67%
% of All Funds
0.32%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
2
Increased
5
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management III
California
+$533K
2
PC
Polar Capital
United Kingdom
+$70.1K
3
US Bancorp
US Bancorp
Minnesota
+$55.5K
4
Deutsche Bank
Deutsche Bank
Germany
+$15.9K
5
UBS Group
UBS Group
Switzerland
+$10.1K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$2.08M

VRNA Hedge Fund Activity: Q1 2018 in Review

14 of the 4,365 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q1 2018, worth a combined $132M — up 66% from $79.3M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VRNA positions and 0 closed out — a net gain of 2 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Foresite Capital Management III, adding an estimated $533K. The largest seller was Perceptive Advisors, cutting an estimated $2.08M.

  • 14 institutional investors held Verona Pharma (VRNA) as of Q1 2018, up from 12 in Q4 2017.
  • Funds reported $132M of Verona Pharma stock for Q1 2018, up 66% quarter-over-quarter.
  • 2 funds opened new Verona Pharma positions in Q1 2018 and 0 closed out, a net change of +2 holders.
  • The largest Verona Pharma buyer in Q1 2018 was Foresite Capital Management III, an estimated $533K added.
  • The largest Verona Pharma seller in Q1 2018 was Perceptive Advisors, an estimated $2.08M sold.

Based on aggregated 13F filings for Q1 2018.